Compugen licenses Selexis’ Cell line-Based Protein Expression Platform

Global life sciences company and a global leader in mammalian cell line generation technology, Selexis SA asserted that Compugen has obtained license to the Selexis SUREtechnology Platform for use in generating high-performance research cell banks (RCBs). A leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy.

Compugen is set to leverage Selexis’ mammalian cell line-based protein expression platform to develop antibody-based therapeutics targeting certain cancers, including to support further advancement of COM701.

Compugen’s lead immuno-oncology product candidate, COM701, is a humanized hybridoma antibody that binds with high affinity to PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen, blocking its interaction with PVRL2. The candidate is currently in preclinical development with an investigational new drug (IND) application filing with the U.S. Food and Drug Administration expected towards the end of the first quarter of 2018.

Yemi Onakunle, PhD, Selexis vice president, business development and licensing said “It is rewarding for us to play a role in the important research and development efforts ongoing at Compugen and we value the opportunity to continue to play a role in enabling our partners to bring much needed treatment options to patients.”